相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients
Hasan Cagin Lenk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data
Yitian Zhou et al.
PHARMACOGENOMICS JOURNAL (2022)
Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41
Ulrich M. Zanger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
Tessa A. M. Mulder et al.
CANCERS (2021)
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
Thomas Helland et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
Maaike van der Lee et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
Yuanhuang Chen et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer
Jeanine Marie Nardin et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans
Pascal Schlosser et al.
NATURE GENETICS (2020)
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Anna Mueller-Schoell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients
Werner Schroth et al.
CLINICAL CANCER RESEARCH (2020)
Long-read sequencing to understand genome biology and cell function
Florian Kraft et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2020)
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study
Alicja Puszkiel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer
Ewa E. Hennig et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Integrating rare genetic variants into pharmacogenetic drug response predictions
Magnus Ingelman-Sundberg et al.
HUMAN GENOMICS (2018)
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
Werner Schroth et al.
FRONTIERS IN PHARMACOLOGY (2017)
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Thomas Helland et al.
BREAST CANCER RESEARCH (2017)
Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility
Daniel L. Hertz et al.
CLINICAL CANCER RESEARCH (2016)
One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity
Daniel L. Hertz et al.
PHARMACOGENOMICS (2016)
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
Kristin G. Ardlie et al.
SCIENCE (2015)
Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation
Marina V. Antunes et al.
THERAPEUTIC DRUG MONITORING (2015)
Functional characterization of CYP2D6 enhancer polymorphisms
Danxin Wang et al.
HUMAN MOLECULAR GENETICS (2015)
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
P. Saladores et al.
PHARMACOGENOMICS JOURNAL (2015)
Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
Hiltrud Brauch et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes
Philipp Y. Maximov et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies
M. P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity
Danxin Wang et al.
HUMAN MOLECULAR GENETICS (2014)
Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 1840 Years at Diagnosis: The POSH Study
Ellen Copson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for OMICs in Low and Middle Income Countries
Zainab Awada et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2013)
Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver
A. Schroeder et al.
PHARMACOGENOMICS JOURNAL (2013)
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
Jennifer Gjerde et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The Relevance of Missing Heritability in Pharmacogenomics
W. Sadee
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
Joanne S. L. Lim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
T. E. Muerdter et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver
Xia Yang et al.
GENOME RESEARCH (2010)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
Genotype-guided tamoxifen therapy: time to pause for reflection?
Timothy L. Lash et al.
LANCET ONCOLOGY (2009)
Mapping the genetic architecture of gene expression in human liver
Eric E. Schadt et al.
PLOS BIOLOGY (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
分享论文
